Abstract
Recent years have seen a change in the treatment options for gastric cancer (GC) from a standard to a tailored approach. Different individualized procedures range from endoscopic resection, D2 with an open or minimally invasive approach, neoadjuvant therapy followed by extended surgery, or the inclusion of hyperthermic intraperitoneal chemotherapy (HIPEC). New molecular classifications of GC have been recently introduced and translational clinical studies are ongoing. These classifications are expected to be included in the multidisciplinary treatment of GC. In particular, in the group with microsatellite instability a less extended lymphadenectomy may be proposed. Also tailored neoadjuvant treatment may be proposed according to molecular classifications. The group of patients with epithelial-to-mesenchymal transition shows very high propensity for peritoneal dissemination as well as N-metastases, and may benefit from prophylactic HIPEC and extended lymphadenectomy, when confirmed in prospective trials.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
